NCT06793397
ClinicalTrials.gov
- Trial ID
- T-ctgov-NCT06793397
- Registry
- ClinicalTrials.gov
- NCT number
- NCT06793397
- CTIS number
- 2024-519270-40-00
- Asset
- HLP003
- Sponsor, as registered
- Cybin IRL Limited
- Phase
- PHASE3
- Indication
- Major Depressive Disorder (MDD);Depression in Adults;Depression - Major Depressive Disorder;Depression Disorders;Depression Disorder;Depression
- Status
- RECRUITING
- Start date
- 2025-12-10
- Primary completion
- 2027-06-07
- Registered countries
- Australia, Czechia, Germany, Greece, Ireland, Poland, United Kingdom, United States
- Sites
- 79
The sponsor's registered location list, which states intent rather than approval.
clinicaltrials.govctgov registryverified 2026-10-06
Notes on the record
Supersedes the rows of the same trial_id verified 2026-10-06 (both kept), per DATA LAYER rule 4; every field but notes is unchanged. Read live from the ClinicalTrials.gov v2 API 2026-10-06 (record last updated 2026-10-05): 79 location entries, 52 RECRUITING, 16 NOT_YET_RECRUITING, 11 WITHDRAWN. The 11 WITHDRAWN, city and country as the registry gives them: Little Rock (Arkansas), Imperial (California), Stanford (California), Atlanta (Georgia), Marrero (Louisiana), Baltimore (Maryland), Oklahoma City (Oklahoma), Austin (Texas), Fort Worth (Texas), all United States; Bialystok, Poland; London, United Kingdom. The registry publishes no date for a site's status, so when each was withdrawn is not recorded.
Company
Through HLP003: Helus Pharma
Cited in
Issues quoting NCT06793397 in their own text.